罗格列酮预防类固醇糖尿病的临床观察

Observation of Rosiglitazone for Prevention of Patients with Steroid Diabetes

目的观察罗格列酮预防类固醇糖尿病的临床疗效。方法实验组选择服用强的松[≥1mg/(kg.d)]的病例25例,同时服用罗格列酮(4mg/d)。对照组选择年龄、体重指数与之相仿的病例35例,单用强的松[≥1mg/(kg.d)]。用药前及用药8周后分别测OGTT、HbA1c、C肽释放,观察各指标用药前后的变化。结果实验组用药前后各指标无明显变化(P>0.05)。对照组用药后OGTT60min、120min、180min血糖较用药前明显升高(P<0.05),且HbA1c较用药前也明显升高(P<0.05)。对照组用药后较实验组用药后OGTT120min、180min血糖明显升高(P<0.05),对照组用药后较实验组用药后HbA1c明显升高(P<0.05)。结论罗格列酮对类固醇糖尿病的发生可能有一定的预防作用。

Objective To observe the efficiency of the Rosiglitazone in the prevention of steroid diabetes.Methods Total 25 cases belong to experiment group were treated with both prednisone[≥1mg/（kg·d）] and Rosiglitazone（4mg/d）.35 cases belong to comparion group were treated with prednisone[1mg/（kg·d）].All cases were assessed by measuring oral glucose tolerance test,HbA1c,and C-P release test at baseline and after treatment for 8 weeks.Results The blood sugar of taking oral glucose 60,120,180 minutes of treatment for 8 weeks of comparion group were higher thanthat of baseline of comparion group（ P 〈 0.05）. HbAlc of treatment for 8 weeks of comparion group was higher than that of baseline of comparion group （ P 〈 0.05 ）. After treatment for 8 weeks, The blood sugar of taking oral glucose 120,180 minutes of comparion group were higer than that of experiment group（ P 〈 0.05）, HbAlc of comparion group was higer than that of experiment group（ P 〈 0. 05）. Conclusion The Rosiglitazone may be an effective drug in the prevention of steroid diabetes.